Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as APD356-lorcaserin hydrochloride, Belviq
APD356-lorcaserin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| APD356-lorcaserin hydrochloride | DRUG | - |
| Placebo | DRUG | - |
APD356-lorcaserin is an investigational small molecule being developed by Pfizer, Inc. (PFE) for smoking cessation. It is in Phase 2 clinical development and has been studied in a completed Phase 2 trial. It is also known as APD356-lorcaserin hydrochloride.
APD356-lorcaserin is being studied for smoking cessation. The completed Phase 2 trial evaluated its effect on smoking cessation in participants who smoke. It is not approved for any indication and remains investigational.
Pfizer, Inc. (ticker: PFE) is the developer of APD356-lorcaserin. Pfizer is responsible for the clinical development program, including the completed Phase 2 trial of the drug in smoking cessation.
APD356-lorcaserin is in Phase 2 clinical development. One Phase 2 trial has been completed, and there are no active trials. The drug is investigational and has not been approved for any use.
APD356-lorcaserin has been studied in one completed Phase 2 trial, NCT02044874, titled "A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation." The trial enrolled 603 participants and was uncontrolled.
Yes, APD356-lorcaserin hydrochloride is another name for APD356-lorcaserin. The hydrochloride form is the specific salt used in the clinical trial, which evaluated lorcaserin hydrochloride for smoking cessation.